Drugs / Bmab 1000
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05323708 | Mar 2022 → Oct 2023 | — | Biocon Biologics UK Ltd | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT05345691 | May 2022 → Jun 2024 | postmenopausal osteoporosis | Biocon Biologics UK Ltd | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bmab 1000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05323708 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT05323708 ↗ |